Completed PHASE1 INTERVENTIONAL 2-arm NCT01665209

Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions

Single Dose Two-Way Crossover Fed Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets in Healthy Volunteers.

Sponsor: Ranbaxy Inc.

Conditions Healthy

Interventions Morphine Sulfate

Updated 4 times since 2017 Last updated: Aug 13, 2012 Started: Oct 31, 2006 Primary completion: Oct 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01665209, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Ranbaxy Inc., it has been updated 4 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ranbaxy Inc.

Data source: Ranbaxy Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.